Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.
Novo Nordisk ( NVO 0.15%) has found phenomenal success in treating patients with obesity and diabetes. *Stock prices used were the afternoon prices of Jan. 1, 2025. The video was published on Jan. 3, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback